Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • META—
  • BTC—
…Loading prices
HIMS

Hims & Hers peptide policy published, but only a narrow door

Sources (8)
  • Good news: The enforcement discretion policy on compounded peptides was published on 30 Oct, with the list of six peptides fixed.
  • Bad news: It is non-enforcement, not approval, and covers only 503A pharmacies, so capacity is limited.
  • Bad news: Comments run to 13 Nov and may add testing and reporting conditions, which would raise compliance costs.

What we watchQ3 results on 9 Nov: peptide launch timing, type of pharmacy, pricing and gross margin guidance.

Read the full notes

The enforcement discretion policy on 503A compounded peptides was formally published on 30 Oct, with the list of six unapproved peptides fixed. That is real progress from White House review to the Federal Register. But it is non-enforcement, not approval, and covers only 503A pharmacies that compound patient by patient against a prescription.

Read more

The comment period from 30 Oct to 13 Nov may add testing and reporting conditions, which would raise compliance costs. The regulatory upside has been realised, but a narrow door is not a moat. What needs verifying is the Q3 report on 9 Nov: the peptide launch timing, which type of pharmacy will be used, and pricing and gross margin guidance.

Key evidence

  • On 28 Oct the US Department of Health and Human Services submitted the 'Enforcement Discretion Policy on 503A Compounded Peptides' to the Federal Register, and it was published on 30 Oct. It spares state-licensed pharmacies and physicians from enforcement when they compound, against individual patient prescriptions, six unapproved peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon (Federal Register 2026-22192, AJMC, NPR, STAT, BioPharma Dive)
  • This is real progress from the 17 Oct submission to the White House Office of Management and Budget for review: the document has been published and the list of six peptides is fixed
  • During the White House review, HIMS met review officials separately on 23 Oct (reginfo.gov Executive Order 12866 meeting record, HIMS representative Sonya Elling, cited by AJMC), so the company is lobbying actively
  • The logic chain: peptides are a high-margin new category that HIMS can use to offset the margin dilution from volume in weight-loss drugs (gross margin fell from 76% to 64% in Q2). The CEO has said publicly that he is very bullish on the category. Third-party reports (The Atlantic, Gounder) say the company plans to sell BPC-157 on prescription once regulation is relaxed
  • Limit 1: it covers only 503A pharmacies that compound patient by patient against a prescription, not 503B outsourcing facilities that make large batches (a pharmacy owner interviewed by NPR complained about this directly). How much of HIMS's own capacity can be used for this will have to wait for company disclosure
  • Limit 2: non-enforcement is not approval, and there is no date. FDA scientists voted against all six (human studies of BPC-157 cover only about 80 people in total). The document states it can be withdrawn if safety signals or quality problems emerge. The Alliance for Safe Medicines has filed a petition to block it
Show 2 more
  • Limit 3: the public comment period runs from 30 Oct to 13 Nov, and the final version may add conditions such as batch-by-batch testing of finished products and deadlines for reporting adverse events, which would raise compliance costs. States may not follow (the Alabama Board of Medical Examiners warned doctors in May not to prescribe research-grade peptides)
  • The compliance undercurrent is unchanged: the Federal Trade Commission lawsuit, and the 2 Nov lead-plaintiff deadline in the securities class action

Catalysts to watch

  • HIMS Q3 results on 9 Nov: peptide launch timing, which type of pharmacy, pricing and gross margin guidance
  • Public comment period closes on 13 Nov; the final version may add testing and reporting conditions
  • Lead-plaintiff deadline in the securities class action on 2 Nov
  • Whether states follow the federal non-enforcement policy
  • Progress in the Federal Trade Commission lawsuit

Risks

  • The 503A narrow door is not 503B scale, so capacity is limited
  • Non-enforcement can be withdrawn, and FDA scientists were unanimously opposed (human data on BPC-157 covers only about 80 people)
  • A final version that adds testing and reporting conditions would push up compliance costs
  • States (such as Alabama) may not follow, or may even warn against it
  • This leg depends more and more on the policy wind, so political risk is rising
  • Compliance undercurrent: the Federal Trade Commission lawsuit and the securities class action

Sources 8

  1. Federal Register 2026-22192
  2. AJMC
  3. NPR
  4. STAT
  5. BioPharma Dive
  6. reginfo.gov Executive Order 12866 meeting record
  7. The Atlantic
  8. Gounder

A brief is a lead for our research, not a verified conclusion or advice.